v3.25.2
Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 11 Months Ended 12 Months Ended
Feb. 13, 2024
Mar. 31, 2024
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Successor          
Cash flows from operating activities:          
Net loss   $ (1,727,483) $ (5,105,931) $ (7,732,212)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Gain from settlement of liabilities with vendors   (141,888) (3,339,223)  
Depreciation expense   76,287 76,294 400,825  
Stock-based compensation   96,289 304,946 924,668  
Amortization of right-to-use operating lease asset   58,659 193,181 609,339  
Share-based inducement expense   156,250    
Amortization of debt discount    
Non-cash interest expense        
Gain on revaluation of earnout and derivative liabilities   (1,800,000) (4,880,000)  
Change in assets and liabilities:          
Prepaid expenses and other current assets   (670,064) (289,715) (87,088)  
Accounts payable   (414,916) 727,912 130,032  
Accrued liabilities   141,982 (299,690) 2,342,593  
Operating lease liability   (61,524) (208,914) (647,503)  
Net cash used in operating activities   (4,442,658) (4,445,667) (12,278,569)  
Cash flows from financing activities:          
Proceeds from issuance of convertible notes        
Issuance costs for convertible notes        
Common stock subscription deposit        
Cash proceeds from exercise of common stock options        
Advances from shareholder   13,731 13,731  
Payment of sponsor loans   (19,715) (19,715)  
Payments for short term borrowings       (402,514)  
Proceeds from exercise of Series A Preferred Warrants   500,000    
Proceeds from short-term borrowings, net   408,052 408,052  
Proceeds from share purchases under ELOC, net of issuance costs       4,809,703  
Proceeds from share purchases under ELOC   1,227,241    
Proceeds from collection of stock subscriptions receivable   716,694    
Proceeds received from sale of common stock   588,000    
Proceeds received from sale of pre-funded warrants, net of issuance costs   3,685,027    
Proceeds from exercise of pre-funded warrants     182    
Cash redemption of Series C Preferred Stock   (395,000)    
Net cash provided by financing activities   7,157,766 6,322,144 13,727,634  
Net increase (decrease) in cash and cash equivalents   2,715,108 1,876,477 1,449,065  
Cash, restricted cash and cash equivalents at beginning of period   1,877,995 3,327,060 1,877,995  
Cash, restricted cash and cash equivalents at end of period $ 1,877,995 4,593,103 5,203,537 3,327,060  
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash and cash equivalents   4,513,347 5,128,781    
Cash and cash equivalents       3,252,304  
Restricted cash   79,756 74,756 74,756  
Cash, restricted cash and cash equivalents 1,877,995 4,593,103 5,203,537 3,327,060  
NON-CASH FINANCING ACTIVITIES:          
Issuance of common shares to Keystone Capital LLC for equity line of credit   633,345 500,000  
Issuance of common shares to Arena Capital Partners for equity line of credit       500,000  
Issuance of Series B shares under subscription agreements   500,000    
Conversion of Series A and Series B preferred stock to common stock   980,985 9,037,773  
Stock subscription receivables       803,044  
Increase in deferred offering costs and accounts payable       112,232  
Exercise of warrants for Series A Preferred Stock through extinguishment of accrued expenses       568,400  
Deemed dividend – common stock liability, 13,835 shares       85,500  
Reclassification of deferred offering costs to additional paid-in capital   112,232    
Reclassification of accrued expenses to accounts payable   1,143,826    
Successor | Series A Preferred Stock          
Cash flows from financing activities:          
Proceeds from issuance of Series Preferred Stock   6,755,698 6,757,700  
Proceeds from exercise of pre-funded warrants       938,800  
Successor | Series B Preferred Stock          
Cash flows from financing activities:          
Proceeds from issuance of Series Preferred Stock       418,316  
Successor | Series C Preferred Stock          
Cash flows from financing activities:          
Proceeds from issuance of Series Preferred Stock       803,561  
Predecessor          
Cash flows from operating activities:          
Net loss (572,211)       $ (7,289,577)
Adjustments to reconcile net loss to net cash used in operating activities:          
Gain from settlement of liabilities with vendors      
Depreciation expense 37,356       460,722
Stock-based compensation 4,431       96,896
Amortization of right-to-use operating lease asset 115,859       656,476
Share-based inducement expense        
Amortization of debt discount (1,875)      
Non-cash interest expense       35,655
Gain on revaluation of earnout and derivative liabilities (320,117)       (290,264)
Change in assets and liabilities:          
Prepaid expenses and other current assets 142,687       (112,321)
Accounts payable 128,429       1,280,560
Accrued liabilities (50,370)       44,239
Operating lease liability (121,589)       (672,373)
Net cash used in operating activities (637,400)       (5,789,987)
Cash flows from financing activities:          
Proceeds from issuance of convertible notes       605,230
Issuance costs for convertible notes       (41,193)
Common stock subscription deposit       1,875
Cash proceeds from exercise of common stock options       5,766
Advances from shareholder      
Payment of sponsor loans        
Payments for short term borrowings      
Proceeds from exercise of Series A Preferred Warrants        
Proceeds from short-term borrowings, net      
Proceeds from share purchases under ELOC, net of issuance costs      
Proceeds from share purchases under ELOC        
Proceeds from collection of stock subscriptions receivable        
Proceeds received from sale of common stock        
Proceeds received from sale of pre-funded warrants, net of issuance costs        
Cash redemption of Series C Preferred Stock        
Net cash provided by financing activities       571,678
Net increase (decrease) in cash and cash equivalents (637,400)       (5,218,309)
Cash, restricted cash and cash equivalents at beginning of period 1,601,255 $ 963,855   $ 963,855 6,819,564
Cash, restricted cash and cash equivalents at end of period 963,855       1,601,255
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash and cash equivalents 963,855        
Cash and cash equivalents 884,099       1,521,499
Restricted cash 79,756       79,756
Cash, restricted cash and cash equivalents 963,855       1,601,255
NON-CASH FINANCING ACTIVITIES:          
Issuance of common shares to Keystone Capital LLC for equity line of credit      
Issuance of common shares to Arena Capital Partners for equity line of credit      
Issuance of Series B shares under subscription agreements        
Conversion of Series A and Series B preferred stock to common stock      
Stock subscription receivables      
Increase in deferred offering costs and accounts payable      
Exercise of warrants for Series A Preferred Stock through extinguishment of accrued expenses      
Deemed dividend – common stock liability, 13,835 shares      
Reclassification of deferred offering costs to additional paid-in capital        
Reclassification of accrued expenses to accounts payable        
Predecessor | Series A Preferred Stock          
Cash flows from financing activities:          
Proceeds from issuance of Series Preferred Stock      
Proceeds from exercise of pre-funded warrants      
Predecessor | Series B Preferred Stock          
Cash flows from financing activities:          
Proceeds from issuance of Series Preferred Stock      
Predecessor | Series C Preferred Stock          
Cash flows from financing activities:          
Proceeds from issuance of Series Preferred Stock